CEP295

Across TCGA pan-cancer cohorts, CEP295 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated CEP295 data layer compared with 29 for mass-spec protein and 2 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher CEP295 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CEP295 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

THYM, UCEC, and KIRP are the cancer types where CEP295 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	III,IV	0.103	0.944	<.001	42	view →
UCEC	DFS	Median	All	0.985	0.818	<.001	32	view →
KIRP	OS	Median	All	0.599	0.903	.003	15	view →
OV	DFS	Median	IV	0.115	0.470	.002	12	view →
ACC	OS	Median	All	0.118	0.624	.038	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

CEP295–THYM (OS)

Open the THYM breakdown →